![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAGOH |
Gene summary for MAGOH |
![]() |
Gene information | Species | Human | Gene symbol | MAGOH | Gene ID | 4116 |
Gene name | mago homolog, exon junction complex subunit | |
Gene Alias | MAGOH1 | |
Cytomap | 1p32.3 | |
Gene Type | protein-coding | GO ID | GO:0000184 | UniProtAcc | P61326 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4116 | MAGOH | GSM4909282 | Human | Breast | IDC | 1.90e-33 | 7.01e-01 | -0.0288 |
4116 | MAGOH | GSM4909285 | Human | Breast | IDC | 9.21e-33 | 6.87e-01 | 0.21 |
4116 | MAGOH | GSM4909286 | Human | Breast | IDC | 7.77e-03 | 2.29e-01 | 0.1081 |
4116 | MAGOH | GSM4909296 | Human | Breast | IDC | 1.51e-03 | 2.61e-02 | 0.1524 |
4116 | MAGOH | GSM4909297 | Human | Breast | IDC | 7.20e-10 | -1.16e-01 | 0.1517 |
4116 | MAGOH | GSM4909311 | Human | Breast | IDC | 2.37e-20 | -1.76e-01 | 0.1534 |
4116 | MAGOH | GSM4909312 | Human | Breast | IDC | 2.26e-05 | -7.17e-02 | 0.1552 |
4116 | MAGOH | GSM4909319 | Human | Breast | IDC | 1.48e-25 | -2.38e-01 | 0.1563 |
4116 | MAGOH | GSM4909320 | Human | Breast | IDC | 4.28e-02 | -1.67e-01 | 0.1575 |
4116 | MAGOH | GSM4909321 | Human | Breast | IDC | 6.26e-13 | -2.70e-01 | 0.1559 |
4116 | MAGOH | brca2 | Human | Breast | Precancer | 1.57e-05 | 2.68e-01 | -0.024 |
4116 | MAGOH | NCCBC14 | Human | Breast | DCIS | 2.00e-02 | -4.98e-02 | 0.2021 |
4116 | MAGOH | NCCBC5 | Human | Breast | DCIS | 2.95e-07 | 2.03e-01 | 0.2046 |
4116 | MAGOH | P1 | Human | Breast | IDC | 1.15e-08 | -1.71e-01 | 0.1527 |
4116 | MAGOH | DCIS2 | Human | Breast | DCIS | 1.84e-64 | 1.82e-01 | 0.0085 |
4116 | MAGOH | AEH-subject1 | Human | Endometrium | AEH | 1.58e-07 | -2.88e-01 | -0.3059 |
4116 | MAGOH | AEH-subject2 | Human | Endometrium | AEH | 2.68e-08 | -2.87e-01 | -0.2525 |
4116 | MAGOH | AEH-subject3 | Human | Endometrium | AEH | 3.26e-06 | -1.93e-01 | -0.2576 |
4116 | MAGOH | AEH-subject4 | Human | Endometrium | AEH | 4.02e-03 | -2.66e-01 | -0.2657 |
4116 | MAGOH | AEH-subject5 | Human | Endometrium | AEH | 3.72e-06 | -2.80e-01 | -0.2953 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0000377113 | Thyroid | PTC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
GO:0000398113 | Thyroid | PTC | mRNA splicing, via spliceosome | 199/5968 | 320/18723 | 2.96e-29 | 1.44e-26 | 199 |
GO:1903311112 | Thyroid | PTC | regulation of mRNA metabolic process | 181/5968 | 288/18723 | 1.60e-27 | 5.94e-25 | 181 |
GO:0006403112 | Thyroid | PTC | RNA localization | 130/5968 | 201/18723 | 9.23e-22 | 1.94e-19 | 130 |
GO:0050684112 | Thyroid | PTC | regulation of mRNA processing | 98/5968 | 137/18723 | 1.53e-21 | 3.10e-19 | 98 |
GO:0043484113 | Thyroid | PTC | regulation of RNA splicing | 102/5968 | 148/18723 | 2.03e-20 | 3.21e-18 | 102 |
GO:0006401112 | Thyroid | PTC | RNA catabolic process | 163/5968 | 278/18723 | 2.13e-20 | 3.27e-18 | 163 |
GO:0006402112 | Thyroid | PTC | mRNA catabolic process | 139/5968 | 232/18723 | 9.59e-19 | 1.12e-16 | 139 |
GO:0006417113 | Thyroid | PTC | regulation of translation | 236/5968 | 468/18723 | 2.70e-17 | 2.52e-15 | 236 |
GO:0034655112 | Thyroid | PTC | nucleobase-containing compound catabolic process | 211/5968 | 407/18723 | 2.72e-17 | 2.52e-15 | 211 |
GO:0000956111 | Thyroid | PTC | nuclear-transcribed mRNA catabolic process | 78/5968 | 112/18723 | 2.37e-16 | 1.94e-14 | 78 |
GO:0048024113 | Thyroid | PTC | regulation of mRNA splicing, via spliceosome | 71/5968 | 101/18723 | 2.39e-15 | 1.71e-13 | 71 |
GO:0046700111 | Thyroid | PTC | heterocycle catabolic process | 221/5968 | 445/18723 | 2.43e-15 | 1.72e-13 | 221 |
GO:0044270111 | Thyroid | PTC | cellular nitrogen compound catabolic process | 223/5968 | 451/18723 | 3.34e-15 | 2.31e-13 | 223 |
GO:0051236110 | Thyroid | PTC | establishment of RNA localization | 100/5968 | 166/18723 | 4.26e-14 | 2.58e-12 | 100 |
GO:0019439111 | Thyroid | PTC | aromatic compound catabolic process | 225/5968 | 467/18723 | 8.51e-14 | 4.71e-12 | 225 |
GO:0050657110 | Thyroid | PTC | nucleic acid transport | 98/5968 | 163/18723 | 9.08e-14 | 4.90e-12 | 98 |
GO:0050658110 | Thyroid | PTC | RNA transport | 98/5968 | 163/18723 | 9.08e-14 | 4.90e-12 | 98 |
GO:1901361111 | Thyroid | PTC | organic cyclic compound catabolic process | 231/5968 | 495/18723 | 2.55e-12 | 1.12e-10 | 231 |
GO:0015931110 | Thyroid | PTC | nucleobase-containing compound transport | 120/5968 | 222/18723 | 5.45e-12 | 2.35e-10 | 120 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa030408 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
hsa0304013 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
hsa0304023 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
hsa0304033 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
hsa0304043 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
hsa0304053 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
hsa030409 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
hsa0304014 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
hsa0304024 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
hsa0304034 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
hsa0304018 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa030159 | Esophagus | HGIN | mRNA surveillance pathway | 30/1383 | 97/8465 | 2.48e-04 | 2.69e-03 | 2.14e-03 | 30 |
hsa030137 | Esophagus | HGIN | Nucleocytoplasmic transport | 31/1383 | 108/8465 | 8.29e-04 | 7.95e-03 | 6.31e-03 | 31 |
hsa0304019 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa0301514 | Esophagus | HGIN | mRNA surveillance pathway | 30/1383 | 97/8465 | 2.48e-04 | 2.69e-03 | 2.14e-03 | 30 |
hsa0301312 | Esophagus | HGIN | Nucleocytoplasmic transport | 31/1383 | 108/8465 | 8.29e-04 | 7.95e-03 | 6.31e-03 | 31 |
hsa0301321 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
hsa0301524 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0301331 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGOH | SNV | Missense_Mutation | c.280G>A | p.Asp94Asn | p.D94N | P61326 | protein_coding | tolerated(1) | benign(0.005) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
MAGOH | SNV | Missense_Mutation | c.185G>T | p.Arg62Ile | p.R62I | P61326 | protein_coding | deleterious(0.03) | possibly_damaging(0.88) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MAGOH | SNV | Missense_Mutation | c.196G>A | p.Asp66Asn | p.D66N | P61326 | protein_coding | deleterious(0.01) | benign(0.071) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MAGOH | SNV | Missense_Mutation | c.293N>A | p.Ser98Tyr | p.S98Y | P61326 | protein_coding | deleterious(0.02) | benign(0.153) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MAGOH | SNV | Missense_Mutation | rs749229462 | c.271N>A | p.Val91Ile | p.V91I | P61326 | protein_coding | tolerated(0.33) | benign(0.023) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGOH | SNV | Missense_Mutation | c.185N>C | p.Arg62Thr | p.R62T | P61326 | protein_coding | deleterious(0.02) | possibly_damaging(0.851) | TCGA-78-7150-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD | |
MAGOH | SNV | Missense_Mutation | novel | c.183G>C | p.Lys61Asn | p.K61N | P61326 | protein_coding | deleterious(0) | possibly_damaging(0.733) | TCGA-92-7340-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAGOH | SNV | Missense_Mutation | novel | c.265N>A | p.Glu89Lys | p.E89K | P61326 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-CV-A6JM-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
MAGOH | SNV | Missense_Mutation | c.373C>G | p.Leu125Val | p.L125V | P61326 | protein_coding | deleterious(0.02) | probably_damaging(0.927) | TCGA-HU-8249-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | CR |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |